It is also difficult to hypothesize whether the overexpression of MIF family signatures in CD4+ T cells of CIS patients reflects the preponderance of a particular CD4 T cell subset during CIS and its eventual pathogenetic contribution. The gene discussed is MIF; the disease is in situ carcinoma.